Publication of List of Manufacturers Revoked from Licensing for the Manufacture of Therapeutic Goods - Orthogen Australia Pty Ltd

Overview

The Therapeutic Goods Act 1989 was enacted by the Parliament of Australia to regulate the provision of therapeutic goods, ensuring they are safe, of acceptable quality, and performing as represented. This Act was introduced to address the need for a robust regulatory framework that safeguards public health by controlling the supply, advertising, and manufacturing of therapeutic goods, including medicines, medical devices, and blood products. The Act aims to protect consumers and patients by ensuring that therapeutic goods available in Australia meet stringent safety, quality, and efficacy standards. This particular revocation notice under Section 41(1)(d) of the Act highlights the regulatory power of the Therapeutic Goods Administration to revoke the licence of a manufacturer when necessary, in this case at the request of the manufacturer, Orthogen Australia Pty Ltd. The policy objective of such revocations is to maintain high standards within the therapeutic goods industry, ensuring continued compliance and public safety.

Scope and Application

The Therapeutic Goods Act 1989 applies to any person or entity involved in the supply of therapeutic goods within Australia. This encompasses a broad range of activities including the manufacture, importation, supply, and advertising of therapeutic goods, which are defined to include medicines, medical devices, blood and blood components, tissues, and human cells used in medical treatments. The Act applies to all therapeutic goods available in Australia, irrespective of whether they are supplied domestically or through interstate or international trade, thus covering both the Commonwealth and state jurisdictions. The Act establishes a national standard for the regulation of therapeutic goods, ensuring safety, quality, and efficacy across the country. Certain classes of therapeutic goods may be exempt from some licensing requirements under specific conditions, but these exemptions are narrowly defined and subject to strict oversight by the Therapeutic Goods Administration. The application and enforcement of the Act can be extended or modified through subordinate legislation and regulations, which provide further detail and specificity to the broad provisions of the primary Act.

Key Provisions

The Therapeutic Goods Act 1989 (the Act) governs the regulation of therapeutic goods in Australia, including medicines, medical devices, and blood products. Section 41(1)(d) of the Act provides the Secretary with the authority to revoke a manufacturer's licence for the production of therapeutic goods under certain circumstances. In this case, the Secretary has revoked the licence of Orthogen Australia Pty Ltd, with the original licence number 162398, which was held by Peter MacCallum Cancer Institute located in East Melbourne, Victoria. The revocation was carried out at the request of the manufacturer itself, as outlined in the notification published in the Gazette. Under the Act, entities like Orthogen Australia Pty Ltd are required to adhere to stringent manufacturing standards and regulatory requirements to maintain their licence. This includes ensuring that their manufacturing practices meet the quality and safety standards set by the Therapeutic Goods Administration (TGA). Failure to comply with these standards can result in the TGA taking action to revoke the manufacturer's licence, as seen in this instance. The revocation of a licence can significantly impact the manufacturer's ability to produce and distribute therapeutic goods in Australia. The Act imposes various obligations on manufacturers of therapeutic goods, including maintaining accurate records of their manufacturing processes, conducting regular inspections, and ensuring that their products meet the necessary safety and efficacy standards. Manufacturers must also notify the TGA of any changes to their manufacturing processes or product formulations. Non-compliance with these obligations can lead to enforcement actions by the TGA, including fines, imprisonment, or both, depending on the severity of the breach. In terms of penalties, the Act stipulates various civil and criminal consequences for breaches of its provisions. For example, under Section 42 of the Act, a person who contravenes the Act can be subject to a civil penalty of up to $222,200 for a corporation and $44,440 for an individual. Additionally, under Section 43, a person who is found guilty of an offence under the Act can be subject to imprisonment for up to five years, a fine of up to $222,200 for a corporation and $44,440 for an individual, or both. The maximum penalties are designed to deter non-compliance and ensure that manufacturers take their obligations under the Act seriously.